Sarilumab
- Generic Name
- Sarilumab
- Brand Names
- Kevzara
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1189541-98-7
- Unique Ingredient Identifier
- NU90V55F8I
- Background
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
- Indication
Sarilumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs); and adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
- Associated Conditions
- Polymyalgia Rheumatica (PMR), Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN7508 and REGN9933, novel monoclonal antibodies targeting Factor XI, showed robust antithrombotic effects with minimal bleeding risk in Phase 2 trials post-total knee replacement. A Phase 3 program is set for 2025. Both antibodies demonstrated safety and efficacy, with REGN7508 superior to enoxaparin and non-inferior to apixaban.
Coronavirus Treatment Companies | Best Healthcare Solutions
COVID-19 treatment companies focus on vaccines, antivirals, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna reduce severe cases, while antivirals like Remdesivir and Paxlovid limit viral replication. Monoclonal antibodies like Bamlanivimab offer early intervention. Supportive care remains crucial. Market growth is driven by COVID-19 spread, new variants, and increased demand for effective therapies. Government investments and rapid vaccine advancements accelerate treatment availability. The global pulmonary drug delivery systems market is projected to reach USD 97.8 billion by 2033.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14
EMA's CHMP recommended 8 new medicines for approval, including Augtyro, Gohibic, and Lazcluze, and 4 biosimilars. Extensions of indication were recommended for 11 existing medicines, while marketing authorisations were refused for Cinainu and Kizfizo. CHMP also recommended Leqembi for Alzheimer's patients with specific genetic profiles and updated safety advice for Mysimba. Applications for Izelvay and Inaqovi were withdrawn.
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In ...
Regeneron Pharmaceuticals is compared against key competitors in the Biotechnology industry, revealing lower P/E, P/B, and P/S ratios suggesting potential undervaluation, but a low ROE indicating lower profitability efficiency. High EBITDA and gross profit levels show strong operational performance, while low revenue growth may be a concern.
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales
Sanofi reports 15.7% Q3 sales growth, driven by vaccine sales and strong business performance, raising 2024 EPS guidance. Dupixent sales up 23.8%, with full-year target confirmed at €13 billion. Pharma launches grew 67.1%, led by ALTUVIIIO, Nexviazyme, and Rezurock. Vaccines sales increased 25.5%, boosted by flu sales and Beyfortus. Opella sales rose 7.9%, supported by Qunol acquisition. R&D expenses grew 12.7%, while SG&A expenses grew 6.4%. Business EPS at €2.86, up 12.2% reported and 17.6% at CER. Four regulatory approvals and four positive phase 3 data readouts achieved. Negotiations underway to transfer a controlling stake of Opella to CD&R. 2024 business EPS guidance upgraded to low single-digit growth at CER.
Related Clinical Trials:
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In
Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.
EMA Recommends Several Medicines in October
EMA's CHMP recommended 10 new medicines for approval, including vaccines Fluad and Flucelax for influenza, and extensions for 6 drugs. Biosimilars Absimky and Imuldosa, and generic Eltrombopag Viatris were also recommended. CHMP maintained its refusal for Masitinib AB Science and withdrew applications for Apremilast Viatris and Epixram.
Several Medicines Recommended by EMA's CHMP in October
The European Medicines Agency's CHMP recommended 10 new medicines for approval, including vaccines Fluad and Flucelax for influenza, and extensions for six drugs. Two biosimilars and two generic drugs were also approved. CHMP confirmed its refusal of Masitinib AB Science for amyotrophic lateral sclerosis and withdrew consideration for Apremilast Viatris and Epixram due to data issues and regulatory strategy changes, respectively.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17
The committee recommended marketing authorisations for ten new medicines, including treatments for haemophilia, influenza, malignant ascites, tuberculosis diagnosis, hereditary transthyretin-mediated amyloidosis, and opioid dependence. Six existing medicines received extensions of indication, while two applications were withdrawn. The CHMP confirmed refusals for conditional marketing authorisations for masitinib and non-renewal for Translarna. Updates to COVID-19 vaccines were also approved. Outi Mäki-Ikola was elected as the new CHMP vice-chair.
Inquiry Into Regeneron Pharmaceuticals's Competitor Dynamics In Biotechnology Industry
Regeneron Pharmaceuticals' PE, PB, and PS ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability. However, low revenue growth raises concerns about market expansion.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath